X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SUVEN LIFE with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SUVEN LIFE vs SANOFI INDIA - Comparison Results

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SUVEN LIFE SANOFI INDIA SUVEN LIFE/
SANOFI INDIA
 
P/E (TTM) x 19.1 33.6 56.9% View Chart
P/BV x 3.5 6.4 55.4% View Chart
Dividend Yield % 1.1 1.4 74.9%  

Financials

 SUVEN LIFE   SANOFI INDIA
EQUITY SHARE DATA
    SUVEN LIFE
Mar-16
SANOFI INDIA
Dec-16
SUVEN LIFE/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs3394,560 7.4%   
Low Rs1444,400 3.3%   
Sales per share (Unadj.) Rs39.21,028.5 3.8%  
Earnings per share (Unadj.) Rs7.5129.0 5.8%  
Cash flow per share (Unadj.) Rs8.8186.0 4.7%  
Dividends per share (Unadj.) Rs2.0068.00 2.9%  
Dividend yield (eoy) %0.81.5 54.6%  
Book value per share (Unadj.) Rs49.0753.6 6.5%  
Shares outstanding (eoy) m127.2823.03 552.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.24.4 141.2%   
Avg P/E ratio x32.434.7 93.2%  
P/CF ratio (eoy) x27.524.1 114.2%  
Price / Book Value ratio x4.95.9 82.9%  
Dividend payout %26.852.7 50.8%   
Avg Mkt Cap Rs m30,732103,174 29.8%   
No. of employees `0001.03.6 26.3%   
Total wages/salary Rs m4163,592 11.6%   
Avg. sales/employee Rs Th5,236.16,537.7 80.1%   
Avg. wages/employee Rs Th436.5991.4 44.0%   
Avg. net profit/employee Rs Th995.5819.8 121.4%   
INCOME DATA
Net Sales Rs m4,99523,686 21.1%  
Other income Rs m194708 27.3%   
Total revenues Rs m5,18924,394 21.3%   
Gross profit Rs m1,2335,281 23.3%  
Depreciation Rs m1671,313 12.7%   
Interest Rs m5415 361.3%   
Profit before tax Rs m1,2054,661 25.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m2551,691 15.1%   
Profit after tax Rs m9502,970 32.0%  
Gross profit margin %24.722.3 110.7%  
Effective tax rate %21.236.3 58.3%   
Net profit margin %19.012.5 151.6%  
BALANCE SHEET DATA
Current assets Rs m4,98615,673 31.8%   
Current liabilities Rs m1,0426,678 15.6%   
Net working cap to sales %79.038.0 207.9%  
Current ratio x4.82.3 203.8%  
Inventory Days Days6176 80.3%  
Debtors Days Days3922 175.4%  
Net fixed assets Rs m3,1268,098 38.6%   
Share capital Rs m127230 55.3%   
"Free" reserves Rs m3,71717,088 21.8%   
Net worth Rs m6,23617,356 35.9%   
Long term debt Rs m4320-   
Total assets Rs m8,07925,400 31.8%  
Interest coverage x23.2311.7 7.5%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.60.9 66.3%   
Return on assets %12.411.8 105.7%  
Return on equity %15.217.1 89.0%  
Return on capital %18.926.9 70.1%  
Exports to sales %87.524.5 357.2%   
Imports to sales %12.228.0 43.7%   
Exports (fob) Rs m4,3715,801 75.3%   
Imports (cif) Rs m6116,627 9.2%   
Fx inflow Rs m4,6667,145 65.3%   
Fx outflow Rs m9426,846 13.8%   
Net fx Rs m3,724299 1,245.6%   
CASH FLOW
From Operations Rs m9223,226 28.6%  
From Investments Rs m-619-1,555 39.8%  
From Financial Activity Rs m-698-1,818 38.4%  
Net Cashflow Rs m-396-147 269.2%  

Share Holding

Indian Promoters % 63.4 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 0.0 14.4 -  
FIIs % 0.0 14.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 36.5 10.5 347.6%  
Shareholders   37,287 15,184 245.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SUVEN LIFE With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  GLENMARK PHARMA  ASTRAZENECA PHARMA  DISHMAN PHARMA  

Compare SUVEN LIFE With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices End Day Flat; Oil and Gas Stocks Lead Losses(Closing)

After opening the day in red, share markets in India witnessed negative trading activity throughout the day and ended the day on a weak note.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SUVEN LIFE SHARE PRICE


Feb 22, 2018 (Close)

TRACK SUVEN LIFE

  • Track your investment in SUVEN LIFE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE SUVEN LIFE WITH

MARKET STATS